The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD Public Deposited

Downloadable Content

Download PDF
  • Purpose The pharmacology of roflumilast, recent dosing revisions, and the integral roles of pharmacists in effective chronic obstructive pulmonary disease (COPD) management are reviewed here. Summary COPD is characterized by progressive airflow limitation and intermittent acute exacerbations of symptoms, which contribute to disease progression, worsening of comorbidities, and reduced health-related quality of life. Patients with COPD may use a variety of pharmacotherapies (in combination with nonpharmacological modalities) to prevent exacerbations, reduce the impact of symptoms, and reduce or prevent COPD progression. Given the complex and multifaceted nature of disease management, pharmacists are uniquely positioned to collaborate with other clinicians to improve treatment adherence and efficacy via a number of diverse avenues in patients with COPD. Central to this endeavor is patient education and counseling regarding their treatment regimen .Conclusion Recent findings from a phase 3 clinical trial demonstrate improved tolerability and reduced treatment discontinuation resulting from the use of an uptitration regimen in patients with severe COPD who initiate therapy with roflumilast. Pharmacists have a central role in effective COPD management, especially with respect to patient education about treatments.
Date of publication
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • SAGE Publications
  • Attribution-NonCommercial 4.0 International
Journal title
  • Journal of Pharmacy Practice
Journal volume
  • 35
Journal issue
  • 3
Page start
  • 445
Page end
  • 454
  • AstraZeneca
  • 1531-1937
  • 0897-1900
Copyright date
  • SAGE Publications

This work has no parents.

In Collection: